Syngene International Ltd

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Despite a recent uptick in price, the stock remains under pressure with a strong sell rating and a deteriorating long-term outlook compared to benchmark indices.

Syngene International Ltd has been downgraded from a Sell to a Strong Sell rating as of 30 July 2026, reflecting a marked deterioration across key investment parameters including financial performance, quality metrics, valuation, and technical indicators. The healthcare services company’s recent quarterly results and market trends have raised significant concerns, prompting a reassessment of its investment appeal.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a marked shift in technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade to a Strong Sell by MarketsMOJO, coupled with a 3.58% decline in daily price, underscores growing investor caution amid weakening price action and subdued relative strength.

Syngene International Ltd, a key player in the Healthcare Services sector, has seen its quality rating downgraded from good to average, reflecting a notable deterioration in its business fundamentals. The downgrade comes amid a challenging financial performance marked by declining profitability, subdued growth, and a weakening return profile, raising concerns for investors amid a broader market that has outperformed the stock significantly over the past decade.

Syngene International Ltd., the contract research and manufacturing services provider, reported a staggering loss of ₹9.00 crores for Q1 FY27, marking a dramatic reversal from the ₹86.70 crores profit posted in Q1 FY26. The 110.38% year-on-year decline in profitability, coupled with a 15.84% revenue contraction, has sent the stock tumbling 4.27% to ₹396.00, extending its brutal year-to-date decline to 39.16%. With a market capitalisation of ₹15,985.30 crores, the company now trades at a precarious 47x trailing twelve-month earnings despite deteriorating fundamentals.

Syngene International Ltd’s stock price declined sharply on 30 Jul 2026, hitting a new 52-week low of Rs.376.9. This marks a significant drop for the healthcare services company, reflecting ongoing challenges in its financial performance and market positioning.

Syngene International Ltd experienced a sharp gap down at the opening on 30 July 2026, reflecting heightened market apprehension. The stock opened 7.4% lower, hitting a new 52-week low of Rs. 376.9, underperforming its sector and broader indices amid a backdrop of cautious sentiment.

Syngene International Ltd experienced significant intraday weakness on 30 Jul 2026, hitting a new 52-week low of Rs. 377.45 as the stock faced intense selling pressure and underperformed its sector and benchmark indices.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has exhibited a nuanced shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.81%, the stock’s broader technical indicators reveal a complex interplay of bullish and bearish signals, underscoring the challenges faced by investors amid a prolonged downtrend relative to benchmark indices.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 July 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from mildly bearish to a more pronounced bearish trend. Recent technical indicators such as MACD, RSI, Bollinger Bands, and moving averages reveal a complex picture of weakening price momentum, signalling caution for investors amid a challenging market backdrop.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite a near-flat day change of 0.02%, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, underscoring the challenges faced by investors amid broader market pressures and sector-specific dynamics.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from key technical indicators such as MACD, RSI, and moving averages, suggests increasing pressure on the share price amid broader market challenges.

Syngene International Ltd commenced trading on 6 July 2026 with a pronounced gap down, opening at a price 6.02% lower than its previous close. This weak start reflects prevailing market apprehensions, with the stock underperforming its sector and broader indices amid a backdrop of cautious investor sentiment.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 July 2026, providing investors with an up-to-date view of its performance and outlook.

Syngene International Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.